Sarepta Therapeutics and Codiak BioSciences Collaborate to Research and Develop Exosome-Based Therapeutics for Rare Diseases

Sarepta Therapeutics, Inc. and Codiak BioSciences, Inc. announced a global research and option agreement to design and develop engineered exosome therapeutics to deliver gene therapy, gene editing and RNA technologies for neuromuscular diseases.
[Sarepta Therapeutics, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

Bio-Techne and ZERO – The End of Prostate Cancer Announce Partnership to Fund Education and Awareness Campaigns to Empower Men with Prostate Cancer

Bio-Techne Corporation announced that Exosome Diagnostics has established a new partnership with ZERO – The End of Prostate Cancer.
[Bio-Techne Corporation]
Press Release
Bookmark

No account yet? Register

0
Share

Principia Presents Updated Positive Data of Rilzabrutinib for Immune Thrombocytopenia in Ongoing Phase I/II Trial

Principia Biopharma, Inc. announced positive data on durability of response from an ongoing Phase I/II trial of its investigational treatment, rilzabrutinib.
[Principia Biopharma, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

US Science Groups Wary of New Senate Bills to Curb Foreign Influences

A bipartisan group of US senators proposed sweeping—and controversial—changes in how the federal government manages academic research in the face of threats from other countries.
[ScienceInsider]
Press Release
Bookmark

No account yet? Register

0
Share

Emmes Announces Its Work on a Phase III Clinical Trial for Breakthrough Therapy Designation Product

Emmes announced that it provided the Phase III clinical trial support for a new investigational cell therapy that offers a promising treatment opportunity for patients who need an allogeneic bone marrow transplant.
[Emmes (PR Newswire, Inc.)]
Press Release
Bookmark

No account yet? Register

0
Share

Creatv Announces Ability to Predict Immunotherapy Treatment Response for Non-Small Cell Lung Cancer Using a Simple Blood Test

Creatv Microtech has pioneered a blood test to predict treatment response in patients with stage II-III NSCLC treated with chemoradiation therapy and consolidated immunotherapy.
[Business Wire, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

Lassen Therapeutics Launches to Discover and Develop Novel Antibody Therapeutics Including Lead Program Targeting IL-11 to Treat Fibrosis and Oncology

Lassen Therapeutics announced it has emerged from stealth and secured $31 million in Series A financing to develop antibodies as potential treatments for fibrosis, rare diseases and oncology.
[Lassen Therapeutics]
Bookmark

No account yet? Register

0
Share

Bellicum Receives FDA IND Clearance to Initiate a Phase I/II Clinical Trial for BPX-603, a Dual-Switch GoCAR-T® for HER2+ Solid Tumors

Bellicum Pharmaceuticals, Inc. announced clearance by the FDA of its investigational new drug application for BPX-603. BPX-603 is a GoCAR-T® product candidate targeting solid tumors that express human epidermal growth factor receptor 2 (HER2).
[Bellicum Pharmaceuticals, Inc.]
Bookmark

No account yet? Register

0
Share

Immune Status Could Determine Efficacy of COVID-19 Therapies

Emerging evidence suggests that SARS-CoV-2 can drive a diverse array of immune processes, raising the risk that immunosuppressant agents that are in clinical trials might be effective for some patients but detrimental for others.
[Nature Reviews Drug Discovery]
Press Release
Bookmark

No account yet? Register

0
Share

How Deadly Is the Coronavirus? Scientists Are Close to an Answer

Researchers use a metric called infection fatality rate (IFR) to calculate how deadly a new disease is. It is the proportion of infected people who will die as a result, including those who don’t get tested or show symptoms.
[Nature News]
Press Release
Bookmark

No account yet? Register

0
Share
Share